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tors for rib fractures were a higher fraction dose (p = 0.040), 
large RT fields, and treatment before the year 2000.
Discussion and conclusion ReRT + HT results in long-term 
LC. The majority of rib fractures were located in the pho-
ton/electron abutment area, emphasizing the disadvantage 
of field overlap. Large abutted photon/electron fields com-
bined with 4 Gy fractions increase the number of rib frac-
tures in this study group. However, as these factors were 
highly correlated no relative importance of the individual 
factors could be estimated. Increasing the number of HT 
sessions a week does not increase the risk of rib fractures.
Keywords Reirradiation · Hyperthermia ·  
Recurrent breast cancer · Local control · Toxicity
Rippenfrakturen nach Rebestrahlung kombiniert 
mit Hyperthermie bei rezidiviertem Brustkrebs
Prognostische Faktoren
Zusammenfassung
Hintergrund Der kombinierte Einsatz von Rebestrahlung 
(reRT) und Hyperthermie (HT) zeigt eine hohe Wirksam-
keit bei Patienten mit lokoregional rezidiviertem Brustkrebs 
(LR). Jedoch können zusätzliche toxische Effekte von reRT 
(z. B. Rippenfrakturen)auftreten. Ziel war es, potentielle 
Risikofaktoren für die Entstehung von Rippenfrakturen zu 
untersuchen.
Patienten und Methoden Von 1982–2005 wurden 234 Pati-
enten nach LR-Operation mit adjuvanter reRT + HT behan-
delt. Die reRT wurde üblicherweise mit 8 × 4 Gy 2/Woche 
oder 12 × 3 Gy 4/Woche durchgeführt. Mit sich anschließen-
den Photonen- und Elektronenfeldern wurden 118 Patienten 
bestrahlt. Eine Bestrahlung mit einem oder mehreren ver-
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Abstract
Background Combining reirradiation (reRT) and hyper-
thermia (HT) has shown high therapeutic value for patients 
with locoregional recurrent breast cancer (LR). However, 
additional toxicity of reirradiation (e.g., rib fractures) may 
occur. The aim of this study is to determine the impact of 
potential risk factors on the occurrence of rib fractures.
Patients and methods From 1982–2005, 234 patients were 
treated with adjuvant reRT + HT after surgery for LR. ReRT 
consisted typically of 8 fractions of 4 Gy twice a week, or 12 
fractions of 3 Gy four times a week. A total of 118 patients 
were irradiated with abutted photon and electron fields. In 
all, 60 patients were irradiated using either one or alternat-
ing combinations of abutted AP electron fields. Hyperther-
mia was given once or twice a week.
Results The 5-year infield local control (LC) rate was 70 %. 
Rib fractures were detected in 16 of 234 patients (actuarial 
risk: 7 % at 5 years). All rib fractures occurred in patients 
treated with a combination of photon and abutted electron 
fields (p = 0.000); in 15 of 16 patients fractures were located 
in the abutment regions. The other significant predictive fac-
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scopic complete resection or a clinically complete remission 
after chemotherapy. The impact of potential risk factors on 
the occurrence of fractures is also investigated.
Methods and materials
Patients
Data were collected from all patients with locoregional 
recurrent breast cancer in areas previously irradiated with 
curative intent, treated with reRT and HT at the Academic 
Medical Center (AMC) and at the Ben Verbeeten Institute 
(BVI). Patients treated from 1982 onward, the year clini-
cal hyperthermia started in the Netherlands, up to 2006 
were included to enable long-term follow-up. A total of 234 
(AMC: 152, BVI: 82) patients received ReRT + HT as an 
adjunct to surgery or chemotherapy.
Data were collected from the radiotherapy and hyper-
thermia patient charts. In case of missing follow-up data, 
questionnaires were sent to referring specialists, and/or gen-
eral practitioners. X-rays and CT scans were collected from 
patients who were reported to have rib fractures on any fol-
low-up visit after reRT + HT. Imaging was performed when 
patients suffered from pain or other symptoms or when dis-
ease progression was suspected. The number and location of 
the fractures were assessed by one of the researchers (C.V.) 
and confirmed by a radiologist (A.R.)
All patients received previous high dose radiation, over-
lapping with the current reRT field. Of the patients, 42 % 
were treated for previous locoregional recurrent disease 
using surgery, radiation, systemic therapy, or a combination 
of treatment modalities, before start of reRT + HT.
For the current recurrence episode, 225 patients had a 
macroscopically complete surgery and 9 patients a clini-
cally complete remission (cCR) after chemotherapy. Char-
acteristics of the current disease episode and potential risk 
factors for rib fractures are summarized in Table 1.
Treatment
Radiotherapy
All AMC patients were irradiated using a standard schedule 
of 8 fractions of 4 Gy given twice a week to a total dose of 
32 Gy. At BVI, the standard reRT schedule consisted of 12 
fractions of 3 Gy given four times a week to a total dose of 
36 Gy. For large target areas, abutted photon and electron 
fields were used at AMC (Fig. 1a). In general, the chest wall 
or mastectomy area up to the dorsal axillary fold was con-
sidered the target area.
At BVI, large target areas were treated with a combina-
tion of 2–3 alternating abutted AP electron fields. Fields 
setzten AP-Elektronenfeldern erhielten 60 Patienten. Die 
HT wurde 1- oder 2-mal pro Woche verabreicht.
Ergebnisse Die lokale Kontrollrate (LC) betrug 70% nach 
5 Jahren. Insgesamt wurden bei 16/234 Patienten Rippen-
frakturen festgestellt (Risiko 7% nach 5 Jahren). Alle Frak-
turen traten bei Patienten auf, die mit einer Kombination 
von Photonen- und Elektronenfeldern behandelt wurden 
(p = 0,000); bei 15/16 Patienten waren Frakturen in der An-
schlussregion lokalisiert. Weitere wichtige prädiktive Fak-
toren für Rippenfrakturen waren eine höhere Fraktionier-
ungsdosis (p = 0,040), große RT-Felder sowie eine Behand-
lung vor dem Jahr 2000.
Diskussion und Schlussfolgerung Durch reRT + HT lässt 
sich eine langfristige LC erzielen. Die Mehrheit der Rip-
penfrakturen war in den Photonen-/Elektronenanschlussre-
gionen lokalisiert, was den Nachteil von Feldüberlappungen 
bekräftigt. Große angrenzende Photonen-/Elektronenfelder 
kombiniert mit 4-Gy-Fraktionen erhöhen die Zahl von Rip-
penfrakturen in dieser Studiengruppe. Da die verschiedenen 
Faktoren stark korrelierten, konnte keine relative Bedeu-
tung der Einzelfaktoren ermittelt werden. Mehr HT-Sitzun-
gen pro Woche erhöhen das Risiko für Rippenbrüche nicht.
Schlüsselwörter Rebestrahlung · Hyperthermie · 
Rezidivierender Brustkrebs · Lokale Kontrolle · Toxizität
Locoregional recurrence (LR) after mastectomy or breast 
conservation predicts a poor outcome in patients with breast 
cancer [1–3]. Hyperthermia (HT), the elevation of tumor 
temperature to 40–45 °C, is a well-established radio- and 
chemotherapy sensitizer [4, 5]. Several phase III trials dem-
onstrated a significant increase of complete response rates 
and duration of local control when hyperthermia was added 
to radiotherapy for locoregional recurrent breast cancer 
in previously irradiated areas [6, 7]. The Dutch National 
guidelines therefore adopted the combination of reirradia-
tion (reRT) + HT as standard of care for recurrent breast 
cancer in previously irradiated area [8].
The reported incidence of rib fractures after primary 
breast cancer treatment varies from < 1 to 19 % [9–13], 
depending on detection methods. The incidence decreased 
to < 2 % in more recent years, due to the improvement of 
radiation techniques [9, 10, 13].
After reRT for recurrent breast cancer, toxicity, like 
rib fractures, are likely to occur as well. Although several 
authors report on the incidence of rib fractures [9–13], data 
on the risk and significant cause(s) of rib fractures after reRT 
+ HT in previously irradiated area are scarce. The current 
study aims to retrospectively evaluate the number and loca-
tion of rib fractures after adjuvant reRT + HT in 234 patients 
treated in two Dutch clinical centers for locoregional recur-
rent breast cancer in previously irradiated area after macro-
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Hyperthermia
HT was given once a week at AMC and twice a week at BVI, 
starting within 1 h after radiotherapy. Heat was induced 
electromagnetically, using externally applied contact flex-
ible microstrip applicators, operating at 434 MHz [14]. 
Treatment fields covered the entire target area. The use of 
one single applicator was sufficient to cover the entire target 
area for all patients. For all patients, temperatures were mea-
sured with thin flexible multisensory thermocouple probes 
on the skin and, if feasible or preferable, invasively using a 
flexible subcutaneous catheter. The target temperature was 
41–43 °C for 1 h, following a preheating phase of approxi-
mately 15 min. Applied power was adjusted to the desired 
temperature distribution without exceeding the maximum 
normal tissue temperatures (45 °C) or patient tolerance.
Endpoints and data analysis
Rib fractures
Rib fractures were graded according to the National Can-
cer Institute’s Common Terminology Criteria for Adverse 
Events, version 3.0 as bone fractures were not included in 
version 4. The rib fracture incidence was calculated by the 
actuarial method of Kaplan and Meier from the start of reRT 
+ HT to the date of first rib fracture notification. Patients 
without rib fractures were censored at date of last follow-
up. The location of rib fractures for each individual patient 
were marked on two standard left/right chest wall CT scans 
relatively to the radiation fields. For one patient locating rib 
fractures was not possible because volumetric data were 
lost. As this patient was reported with radiation-induced rib 
fractures, we did include this patient in the statistical analy-
sis and EQD2 calculations.
Local control and survival
Both local control (LC) and survival rate were calculated 
from the date of first re-irradiation fraction. Duration of 
LC and survival were analyzed by the actuarial method 
of Kaplan and Meier. Local failure was defined as in-field 
relapse. Patients dying with LC, or alive with continuing LC 
at last follow-up, were censored at the date of death or last 
follow-up, respectively.
Statistics
Statistical analysis was carried out using SPSS version 20 
(SPSS Inc., Chicago, IL, USA). A univariable analysis was 
done for the occurrence of rib fractures, using patient, dis-
ease, and treatment related variables. A total of 14 variables 
with potential prognostic value were tested. Only variables 
are separated by gaps, creating a number of different fields. 
Alternatingly, either 2 or 3 fields will be irradiated simulta-
neously. The distance between the alternating gap locations 
was adjusted for each individual patient to minimize both 
underdosage and overdosage (Fig. 1b).
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35 (43 %) 66 (44 %) 101 (44 %)
 Chest wall resec-
tion (CWR)
4 (5 %) 12 (8 %) 16 (7 %)
 Wide resection/
partial CWR
3 (4 %) 4 (3 %) 7 (3 %)
 Local excision 36 (44 %) 63 (42 %) 99 (43 %)
 Chemotherapy 4 (5 %) 5 (3 %) 9 (4 %)









 10/20/25 × 2 
(20/40/50) Gy
1 (1 %) 2 (2 %) 3 (1 %)
 6/10/11 × 3 
(22.2/37/40.7) Gy
3 (3 %) 1 (2 %) 4 (2 %)
 12 × 3 (44.4) Gy 77 (94 %) 77 (33 %)
 5/6 × 4 (23.3/35.2) 
Gy
3 (1 %) 3 (1 %)
 8 × 4 (46.9) Gy 1 (1 %) 139 (91 %) 140 (60 %)
 10 × 4 (58.6) Gy 7 (4 %) 7 (3 %)
















42 (51 %) 83 (55 %) 125 (53 %)
 Chemotherapyn 18 (22 %) 26 (17 %) 44 (19 %)
 Hormone therapyo 33 (40 %) 67 (54 %) 100 (44 %)
Median 
electron-energyp
9 (4–15) MeV 8 (6–15) MeV 8 (4–15) MeV
Table 1 Patient and treatment characteristics
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dose on the ribs. Calculations were done for perfectly abut-
ted photon/electron fields (6 MV photons without bolus, 
10 MeV electrons with bolus).
For alternating abutted electron fields with gaps in 
between, the maximum possible overdose on the ribs was 




In 16 of 234 patients (7 %) 1–8 fractures occurred after reRT 
+ H, whereby 15 of those patients were treated at AMC and 
1 at BVI. The maximum risk increased to 12 % at 6.2 years 
(Fig. 2). Five patients had asymptomatic rib fractures (grade 
1), 7 patients had symptomatic fractures (grade 2), and the 
other 4 patients had grade 3 fractures for which hyperbaric 
oxygen treatment was indicated. The location of rib frac-
tures is shown in Fig. 3a and b. All fractures occurred in the 
reRT area. The number of rib fractures per patient ranged 
from 1–8. Rib 4 was most frequently fractured. In all 15 
AMC patients, fractures were located in the photon/electron 
abutment area anterolateral in the patient. The chart from 
the patient who lacked radiologic data also reported the 
fractures to be in this abutment area. In one patient frac-
tures occurred both in reRT abutment area and in the area of 
overlap with the previously irradiated parasternal field. The 
only BVI patient with rib fractures was treated with tangen-
tial photon fields + 2 abutted electron fields. Although this 
patient did have rib fractures, the fractures were not located 
in the abutment regions. The group of 17 patients treated 
with other RT schedules (Table 2) did not show rib fractures.
The 5 year infield LC rate was 70 % with an overall sur-
vival rate of 60 %.
available for at least 80 % of the population were included. 
The level of statistical significance was considered < 0.05 
for all analyses. Analyses were carried out using the Cox 
regression test or the Fisher’s exact test, depending on the 
number of events. The continuous variables were checked 
for linearity by using spline regression curves and spline 
coefficients tested for nonlinearity; all continuous variables 
showed a linear relationship with the occurrence of rib frac-
tures. A multivariable analysis was not deemed appropriate 
because of the small total number of events.
Equivalent dose at 2 Gy (EQD2)
The maximum possible EQD2 at the rib area was calculated 
for the two different reRT fraction doses and for the two 
different reRT techniques, using the linear-quadratic (LQ) 
model [15]:
where D denotes the total reRT dose and d the dose per frac-
tion. α/β was assumed to be 2.3 Gy for the ribs [15]. The 
maximum possible overdose on the ribs when using abutted 
electron/photon fields was calculated using the AMC plan-
ning system (Oncentra, v.4.3, Elekta). A standard CT scan 
from 2 breast cancer patients were used for simulating dose 
distributions and calculating the maximum possible over-
EQD2 = × + +D d[( ) )]/ /   /α β α β2Gy
Current episode BVI AMC Total
Median 
photon-energyq
6 (6–15) MV 6 (5–14) MV 6 (5–15) MV
TI time interval, FU follow-up, BVI Ben Verbeeten Institute, AMC 
Academic Medical Center
aBVI: missing for 16 patients, AMC: missing for 17 patients
bBVI: missing for 4 patients, AMC: missing for 9 patients
cBVI: missing for 1 patient, AMC: missing for 2 patients
dPrior to reRT + HT; AMC: missing for 2 patients
eBVI: for 2 patients, AMC: data missing for 15 patients
fIn addition to the reRT + HT
gAMC: missing for 1 patient
hBVI: missing for 5 patients
iBVI: missing for 6 patients, AMC: missing for 20 patients
jBVI: missing for 1 patients, AMC: missing for 9 patients
kDose in EQD2 excl. boost; BVI: missing for 1 patient, AMC: missing 
for 11 patients
lPre-reRT local or regional boost overlapping the current reRT area 
given for previous recurrent disease
mTotal dose boost in EQD2
nTotal pre-reRT dose incl boost in EQD2
Oin parenthesis dose in EQD2
pDose in EQD2; BVI: missing for 1 patient, AMC: missing for 1 patient
qTotal reRT dose in EQD2, incl 40 % of the total pre-reRT dose; BVI: 
missing for 2 patients, AMC: missing for 12 patients. α/β = 2.3
Table 1 (continued)
Fig. 1 Standard chest wall radiation technique. a One anterior–poste-
rior electron field abutted to one anteroposterior–posteroanterior pho-
ton field. b Alternating use of 2 or 3 abutted anteroposterior electron 
fields separated by either 1 or 2 small gaps
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cantly affect rib fracture incidence. The use of abutted pho-
ton/electron fields significantly contributed to the incidence 
of rib fractures compared to all other RT techniques. A frac-
tion dose of 4 Gy resulted in a significantly 9-fold higher 
risk on rib fractures compared to 3 Gy. Smaller field sizes 
and year of treatment from 2000 and above reduced the risk 
on rib fractures. Pre-reRT dose, reRT dose and total dose in 
EQD2, not corrected for reRT technique, were not signifi-
cantly related to the occurrence rib fractures.
EQD2
The 12 fraction of 3 Gy schedule, used at BVI can result in 
a EQD2 of 44 Gy in the rib area, when part of the rib cage 
is located within the radiation field. The 8 fractions of 4 Gy 
schedule, used at AMC, would result in a slightly higher 
EQD2 of 47 Gy. Simulation results for perfectly abutted 
photon/electron fields showed the local overdose on part of 
the ribs to vary between 0 and 40 %. The maximum possible 
EQD2 on the ribs with a 40 % overdose would then be 87 Gy 
for 8 fractions of 4 Gy. This is 74 % higher than the TD 5/5 
(EQD2 = 50 Gy; the dose likely to produce rib fractures in 
5 % of patients within 5 years after radiation exposure) [16].
Prognostic factors
The results from these analyses are presented in Table 2. 
The covariates and their measure on entry in the analyses 
are shown in column 1. Four factors were found to signifi-
Fig. 2 Actuarial rib fracture incidence. ---- = 95 % confidence interval, 
+ = censored, ǀ= at risk
 
Fig. 3 Chest wall CT-sans of two 
random breast cancer patients 
showing the AMC treatment plan 
setup: a Left chest wall. b right 
chest wall, different patient. Each 
color represents rib fractures of 
an individual patient. In red frac-
tures in rib 5, 9 and 10 are indi-
cated for a patient which were not 
associated with abutment regions. 
γ photon field. e− electron field
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mary radiation [9, 10, 13]. Our reported fracture rate might 
actually be higher than reported here due to the retrospec-
tive character of our study.
The main differences in reRT treatment between both 
institutes were number of HT fractions, reRT field size, 
-schedule, and -technique. In all, 76 % of BVI patients were 
treated with only one electron field or 2–3 abutted alternat-
ing electron fields (Fig. 1) and a lower reRT fraction dose 
was used, whereby 73 % of AMC patients were treated with 
APPA abutted photon/electron fields, and in general reRT 
fields were larger.
Univariable analyses showed the use of abutted photon/
electron fields to significantly affect the risk on rib fractures 
in agreement with the results from Fig. 3. ReRT fraction 
dose, field size, and year of treatment also significantly 
affected the occurrence of rib fractures. Multivariable 
analyses could not be done, because of the small number of 
events. However, our findings are in agreement with known 
risk factors for primary high dose irradiation: hypofraction-
ation, low machine energy, large target volume, older age, 
female gender, postmenopausal status, surgical procedure 
preceding irradiation, and adjuvant simultaneous or sequen-
tial chemotherapy [11, 12].
The separate effects of abutted fields, fraction dose, and 
field sizes could not be estimated because of the high cor-
relation of these factors. As the other tested factors were 
equally distributed between the two institutes, but not found 
significant, they were considered of lesser predictive value 
for rib fractures in our patient population. The significant 
impact of year of treatment on rib fracture occurrence may 
be related to the availability of improved RT techniques 
after 1999. In 2000 computer tomography-based diagno-
sis and RT planning allowed target areas to be delineated 
more precisely, reducing the risk of normal tissue damage. 
After the year 2000, the risk on rib fractures significantly 
decreased at AMC (P = 0.037, HR = 0.318), but not at BVI 
as the number of fractures observed at BVI was already low 
(1 %). The rib fracture rate for patients treated at AMC from 
2000–2005 was still as high as 6 %, probably reflecting the 
unchanged presence of risk factors such as large abutted 
fields combined with high fraction dose.
Few studies have reported on rib fracture incidence 
with different radiation schedules, after reRT for recurrent 
breast cancer (Table 3). Comparison with those studies is 
difficult because most studies included very few patients, 
RT techniques differ and follow-up times are generally too 
short, as patients can develop fractures between 1 month 
and 5 years after treatment [12]. Some larger retrospec-
tive studies reported on rib fractures after using the same 
reRT schedule as used at AMC. A study by van der Zee et 
al. [17] reported on 8/134 patients (7 %) with bone necrosis 
or fracture. Another study, done by the same institute, did 
not report rib fractures for patients with resectable breast 
When using 12 fractions of 3 Gy and alternating elec-
tron fields separated by gaps (4.5–9 MeV, with 0.5 or 1 cm 
bolus) the local calculated overdose on the ribs varied from 
0–10 %. The EQD2 on the ribs with a 10 % overdose is 
51.6 Gy, exceeding the TD 5/5 by 3 %.
Discussion
We found a difference in rib fracture rate of 1 vs. 10 % for 
the different treatment institutes (BVI vs. AMC). The AMC 
fracture rate is higher than the < 2 % rate reported for pri-
Table 2 Univariable Cox regression for rib fracture incidence








ReRT techniquea: 0.173 0.128 0.000 a
 e− + γ : other
reRT fraction dose: NA NA 0.033 9.049
 3 Gy (BVI): 4 Gy (AMC)
ReRT dose: 0.922 0.915 0.312 1.079
 Continuous (in EQD2)
Total ReRT dose 0.831 0.749 0.628 1.028
 Continuous (in EQD2)
reRT field sizeb: 0.740 0.271 0.047 3.612
 ≤ 2.3: > 2.3 dm2
Year of treatment: 0.673 0.037 0.040 0.344
 ≤ 1999: ≥ 2000
TI current surgery—reRT: 0.592 0.113 0.104 0.537
 < 2: ≥ 2 months
Current surgery: 0.602 0.669 0.505 1.437
 Local excision: Mastectomy
Chemotherapy treatmentc: 0.596 0.154 0.127 2.203
 No: Yes
Age: 0.205 0.409 0.252 0.975
 Continuous
Electron-energy: 0.311 0.447 0.535 1.089
 Continuous (4–15 MeV)
TI primary RT—ReRT: 0.747 0.258 0.356 0.606
 < 65: ≥ 65 months
Menopausal status: 0.668 0.211 0.494 1.682
 Pre: Post
Hormone treatmentc: 0.648 0.148 0.444 0.680
 No: Yes
Photon- energy: NA 0.827 0.820 0.955
 Continuous (5–15 MV)
Total Pre-reRT dose  
(in EQD2):
0.250 0.638 0.605 0.966
 Continuous
TI time interval, HR razard ratio; e− + γ; abutted photon/electron 
fields, NA not applicable, BVI Ben Verbeeten Instituteγ, AMC 
γAcademic Medical Centerγ
aFisher’s exact test; no HR calculable
bMissing values: 7 %
cPrevious treatment or in addition to the reRT + HT
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other HT studies that indicate that the number of HT ses-
sions does not influence toxicity and that hyperthermia does 
not significantly affect overall toxicity when added to (re)
RT [6, 7, 26, 27].
Our patients will be more prone to reRT damage as they 
received high dose irradiation and different kinds of sys-
temic therapies in the past and reRT is preceded by surgery. 
Avoiding large abutted fields and reducing fraction dose 
might therefore also reduce overall toxicity. As a result of 
this study, RT techniques using only tangential photon fields 
or IMRT and lower fraction doses have been adopted at 
AMC in order to minimize the risk of problems with abut-
ting fields.
Conclusion
ReRT + HT results in long-term LC of 70 % after 5 years. 
In 7 % of patients, rib fractures occurred, the majority of 
which were located in the photon/electron abutment area, 
emphasizing the disadvantage of field overlap. Large abut-
ted photon/electron fields combined with 4 Gy fractions 
increased the number of rib fractures in this study group. No 
relative importance of the individual factors could be esti-
mated. Increasing the number of HT sessions a week does 
not increase the risk of rib fractures.
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recurrences [18]. Several reasons might account for this dis-
crepancy. First, only a minority of patients were irradiated 
with photon/electron fields (23 %). Second, only late grade 
3 and 4 toxicities were reported, which included 5 patients 
who required treatment with necrotomy, reconstruction, 
and/or hyperbaric oxygen for osteoradionecrosis. Thus, the 
actual rib fracture rate was probably underreported in their 
third study. Several small sized studies show low frequen-
cies (≤ 1 %) of rib fractures with hyperfractionation [19–23]. 
In general, higher fractions doses seemed to be related to 
higher rib fracture incidences, regardless of the total reRT 
dose. This is in agreement with results from randomized 
phase III trials comparing radiation schedules with fraction 
doses varying from 2.3 versus 3.9 to 2.7–3.2 versus 2 Gy. 
These results indicated that fraction dose could be a fac-
tor in the development of rib fractures above a threshold 
(approximately 3.2–3.9 Gy) even when the total dose is 
modest [10, 11, 13].
Abutted fields are known to cause dosimetric problems 
as overlapping fields can result in a substantial local over- or 
underdose, especially at a depth correlating with the loca-
tion of the ribs.The maximum physical overdose varies with 
patient anatomy, and photon/electron energy and can be 
even be further exceeded by human or mechanical errors. 
When combining 3 Gy fractions with alternating electron 
fields the risk of overdose is minimized.
Both qualitative and quantitative analyses of our patient 
group suggest that abutted photon/electron fields and a 4 Gy 
fraction dose increase the risk of rib fractures and might lead 
to the “double trouble” effect of (1) difference between cal-
culated dose and actual dose at any point and (2) variation in 
biological effects with different fraction doses) when com-
bined [24]. Restoration of normal tissue tolerance after low 
and moderate initial RT doses is on average no more than 
60 % after 6 months, depending on tissue type [25]. Hence, 
for determining the optimum reRT schedule a number of 
parameters must be taken into account: the initial EQD2, 
volume treated, amount of overlap, additional treatments, 
and time interval between therapy courses [25].
Doubling HT fractions did not affect rib damage in our 
study population. This is in agreement with results from 
Table 3 Previous studies of external beam repeat chest wall irradiation for recurrent breast cancer using different ReRT schedules
Study Median FU 
(months)






Rib fractures reRT technique elec-
trons + photons
Li et al. 20 (6–179) 41 HT Med 43.0 Gy 1.8–2.0 Gy 0 (0 %) 0 (0 %)
Deutsch 19 51.1 39 Surgery 50 Gy 2.0 Gy 0 (0 %) 0 (0 %)
Zee vd et al. 17 (1–2 years) 121 HT 32 Gy 4 Gy 8 (7 %) ?
Müller et al. 21 41 42 Surgery + HT Med 60 Gy 1.8–2 Gy 1 (2 %) 0 (0 %)
Wahl et al. 22 17 70 HT/CT Med 48 Gy 1.8–2 Gy 1 (1 %) 4 (6 %)
Linthorst et al. 18 42 198 Surgery + HT 32 Gy 4 Gy 0 (0 %) 45 (23 %)
Wurschmidt et al. 23 13.7 29 ± CT Med. 50.4 Gy 1.6–2.5 Gy 1 (3 %) ?
CT chemotherapy, HT hyperthermia, Med median, PRDR pulsed reduced dose-rate radiotherapy, FU follow-up
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